Advertisement
SANA vs VIR
Which Stock Would AI Choose? Sana Biotechnology (SANA) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- Sana Biotechnology is advancing engineered cell therapies for type 1 diabetes and blood cancers, while Vir Biotechnology is focused on infectious disease and oncology T-cell engagers.
- Vir holds a substantially larger cash position (about $809 million) with a runway into 2028, whereas Sana's roughly $160 million balance sheet implies a shorter runway and higher potential dilution risk.
- Sana has reported narrowing net losses and progress toward an Investigational New Drug (IND) filing for its SC451 diabetes candidate; Vir has logged wider quarterly losses despite a high-value Astellas collaboration.
- Both stocks carry consensus "Buy" ratings, but analyst price targets imply a wider upside spread for Sana given its much lower share price.
- The two names expose investors to different risk profiles: Sana is an early-stage, cash-constrained platform story, while Vir is a better-capitalized, more diversified clinical pipeline.
Introduction
Biotechnology investors often weigh clinical-stage names on two dimensions: the scale of the scientific opportunity and the durability of the balance sheet. This stock comparison places SANA and VIR side by side because both are pre-revenue, development-stage companies whose market positioning hinges on near-term clinical catalysts rather than current earnings. Sana's engineered-cell platform targets large chronic and oncologic markets, while Vir blends an infectious-disease franchise with an expanding oncology pipeline. For traders and long-term investors evaluating relative performance and risk-adjusted exposure in the biotech sector, understanding these contrasting models, funding situations, and momentum drivers is essential.
SANA Overview and Recent Performance
SANA, or Sana Biotechnology, develops engineered cells as medicines, anchored by its Hypoimmune platform designed to generate cells that evade immune rejection without immunosuppression. Its lead programs include SC451, a stem-cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, an in vivo CAR T (chimeric antigen receptor T-cell) approach for B-cell diseases. The company has indicated plans to file an IND for SC451 as early as 2026 and begin Phase 1 testing shortly thereafter.
In recent market activity, Sana has traded in the low single digits, with a market capitalization near $1 billion. The company has narrowed its net loss on both a quarterly and year-to-date basis, and its non-GAAP operating cash burn (a measure of cash consumed by ongoing operations, excluding certain one-time and financing items) declined in the first half of 2026. However, its cash balance of roughly $160 million, alongside substantial contingent consideration liabilities, underscores a comparatively short runway and the prospect of further dilution. Analyst sentiment remains constructive, with a consensus "Buy" and price targets well above current trading levels.
VIR Overview and Recent Performance
VIR, or Vir Biotechnology, is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its pipeline centers on tobevibart plus elebsiran for chronic hepatitis delta, supported by positive Phase 2 SOLSTICE data, and a family of dual-masked T-cell engagers (TCEs) in oncology, led by the PSMA-targeted VIR-5500 in prostate cancer. Vir recently closed a global collaboration with Astellas valued at up to $1.7 billion and anticipates pivotal Phase 3 trials for VIR-5500 in 2027.
In recent weeks, Vir has traded in the single digits despite year-to-date gains, reflecting a stock that has seen sharp moves tied to clinical readouts and partnership announcements. The company reported a wider net loss in its latest quarter as research and development spending remained elevated, yet it ended the period with about $809 million in cash and investments and expects that balance to fund operations into the second half of 2028. Analysts maintain a consensus "Buy" with an average price target materially above recent trading levels.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-powered trading bots, drawn from hundreds of available bots that collectively trade thousands of different tickers. Because market conditions shift continuously, only the bots most suitable for the current environment earn a place in this section. Each robot is built on a distinct trading style, strategy, timeframe, performance profile, and set of tickers, so traders can evaluate bots ranging from conservative to aggressive approaches across varying holding periods. By reviewing the featured robots and their live statistics, users can identify automated strategies aligned with their own objectives and risk tolerance. Explore the Trending AI Robots section to see which strategies are currently leading.
Head-to-Head Comparison
The clearest contrast between these two stocks lies in business focus and financial durability. Sana is concentrated on regenerative and in vivo cell engineering for diabetes and B-cell malignancies, an area with transformative potential but limited near-term proof and a thinner balance sheet. Vir, by contrast, operates across two therapeutic areas and has monetized part of its oncology pipeline through the Astellas partnership, giving it a longer runway and more diversified catalysts.
On growth drivers, Sana's story rests on upcoming human proof-of-concept data for SC451 and SG293, while Vir's momentum is tied to ECLIPSE registrational data in hepatitis delta expected around late 2026 and expanding oncology readouts. Risk factors also diverge: Sana faces elevated financing and dilution risk, whereas Vir carries execution risk across multiple late-stage trials and broader R&D spending that has widened quarterly losses.
Sector exposure differs meaningfully. Both are biotechnology, but Sana skews toward cell therapy and autoimmune-metabolic disease, while Vir spans infectious disease and immuno-oncology. Market sentiment for both remains broadly positive among analysts, though Vir's stronger cash position contrasts with Sana's more speculative, higher-upside profile.
Tickeron AI Verdict
Based on observable factors such as balance-sheet durability, catalyst diversity, and trend consistency, Tickeron's AI would likely lean toward Vir Biotechnology in the current environment. Vir's substantially larger cash reserve, extended runway into 2028, and multiple near-term data catalysts across oncology and hepatitis delta provide a more stable foundation than Sana's narrower, cash-constrained platform. That said, Sana's lower valuation and concentrated clinical optionality could appeal to risk-tolerant investors seeking higher potential upside. The AI's preference reflects relative positioning and stability rather than a definitive outcome, and either stock could re-rate rapidly as clinical data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SANA is a Hold and VIR is a Hold.
SANA's RSI Indicator ascends from oversold territory
The RSI Oscillator for SANA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In 38 of the 40 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 190 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
SANA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SANA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.513) is normal, around the industry mean (3.043). P/E Ratio (-3.107) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR in downward trend: 10-day moving average moved below 50-day moving average on October 22, 2026
The 10-day moving average for VIR crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 73 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
VIR moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 59 cases where VIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 202 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 125 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (3.043). P/E Ratio (-5.972) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR | ||
|---|---|---|
OUTLOOK RATING 1..100 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 42 | |
P/E GROWTH RATING 1..100 | 60 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| SANA | VIR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 68% |
| Momentum ODDS (%) | N/A | 1 day ago 80% |
| MACD ODDS (%) | N/A | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 77% |
| Advances ODDS (%) | 4 days ago 79% | 4 days ago 76% |
| Declines ODDS (%) | 10 days ago 88% | 2 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SANA’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- SANA’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SANA’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).
- SANA’s TA Score: 4 bullish, 2 bearish.
- VIR’s TA Score: 4 bullish, 5 bearish.
Price Growth
SANA (@Biotechnology) experienced а +2.64% price change this week, while VIR (@Biotechnology) price change was +6.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
SANA is expected to report earnings on Nov 05, 2026.
VIR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | -1.69% | ||
| EDIT - SANA | 57% Loosely correlated | -3.61% | ||
| CRSP - SANA | 57% Loosely correlated | -1.20% | ||
| RCKT - SANA | 56% Loosely correlated | -0.87% | ||
| BEAM - SANA | 55% Loosely correlated | -2.08% | ||
| MGTX - SANA | 54% Loosely correlated | -5.73% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | +1.34% | ||
| BEAM - VIR | 55% Loosely correlated | -2.08% | ||
| DNLI - VIR | 53% Loosely correlated | -1.34% | ||
| EDIT - VIR | 52% Loosely correlated | -3.61% | ||
| PRME - VIR | 51% Loosely correlated | -1.61% | ||
| SLDB - VIR | 51% Loosely correlated | -4.36% | ||
More | ||||